4 Best Undervalued Stocks With Great Momentum for January 2026
Welcome to the Value Sense Blog, your resource for insights on the stock market! At Value Sense, we focus on intrinsic value tools and offer stock ideas with undervalued companies. Dive into our research products and learn more about our unique approach at valuesense.io
Explore diverse stock ideas covering technology, healthcare, and commodities sectors. Our insights are crafted to help investors spot opportunities in undervalued growth stocks, enhancing potential returns. Visit us to see evaluations and in-depth market research.
Market Overview & Selection Criteria
In the current market environment, investors are seeking undervalued stocks with great momentum amid volatility in technology, consumer goods, and emerging AI sectors. ValueSense applies a rigorous methodology focusing on high quality ratings (10.0 across selections), intrinsic value comparisons, strong margins, and growth potential despite recent 1Y returns. Stocks are chosen based on robust financial metrics like revenue growth, ROIC, and FCF generation, prioritizing companies trading below their calculated intrinsic value for potential upside. This watchlist highlights four picks analyzed through ValueSense data, offering educational insights into best value stocks and stock picks for diversified portfolios.
Featured Stock Analysis
Stock #1: Workday, Inc. (WDAY)
| Metric | Value |
|---|---|
| Market Cap | $54.4B |
| Quality Rating | 10.0 |
| Intrinsic Value | $218.6 |
| 1Y Return | -18.3% |
| Revenue | $9,216.0M |
| Free Cash Flow | $2,585.0M |
| Revenue Growth | 3.4% |
| FCF margin | 28.0% |
| Gross margin | 77.5% |
| ROIC | 8.1% |
| Total Debt to Equity | 42.7% |
Investment Thesis
Workday, Inc. (WDAY) stands out with a perfect Quality rating of 10.0 and an intrinsic value of $218.6, suggesting significant undervaluation in the enterprise software space. The company reports a substantial Market Cap of $54.4B, Revenue of $9,216.0M, and impressive Free Cash Flow of $2,585.0M, underpinned by a healthy FCF margin of 28.0% and Gross margin of 77.5%. Despite a 1Y Return of -18.3%, modest Revenue growth of 3.4% and ROIC of 8.1% indicate operational efficiency, with manageable Total Debt to Equity at 42.7%. This positions WDAY as a stable tech play for investors analyzing WDAY analysis and long-term value in cloud-based HR and finance solutions.
The metrics reveal a cash-generative business with high margins, ideal for those exploring undervalued growth stocks in technology. ValueSense data emphasizes its quality, making it a core holding in momentum-driven watchlists.
Key Catalysts
- Strong FCF of $2,585.0M supports reinvestment and shareholder returns
- Exceptional Gross margin 77.5% and FCF margin 28.0% highlight profitability
- Perfect Quality rating 10.0 signals superior fundamentals
- Solid ROIC at 8.1% for efficient capital use
Risk Factors
- Recent 1Y Return of -18.3% reflects market pressures on tech valuations
- Modest Revenue growth of 3.4% may lag high-growth peers
- Total Debt to Equity at 42.7% requires monitoring in rising rate environments
Stock #2: Haleon plc (HLN)
| Metric | Value |
|---|---|
| Market Cap | $45.3B |
| Quality Rating | 10.0 |
| Intrinsic Value | $13.0 |
| 1Y Return | 5.9% |
| Revenue | £13.8B |
| Free Cash Flow | £1,396.5M |
| Revenue Growth | 22.2% |
| FCF margin | 10.1% |
| Gross margin | 63.2% |
| ROIC | 8.4% |
| Total Debt to Equity | 52.8% |
Investment Thesis
Haleon plc (HLN), a consumer health leader, earns a top Quality rating of 10.0 with an intrinsic value of $13.0, indicating undervaluation relative to its Market Cap of $45.3B. Key metrics include Revenue of £13.8B, Free Cash Flow of £1,396.5M, robust Revenue growth of 22.2%, and FCF margin of 10.1%, complemented by a Gross margin of 63.2% and ROIC of 8.4%. A positive 1Y Return of 5.9% outperforms peers, though Total Debt to Equity stands at 52.8%. This analysis frames HLN as a defensive pick in healthcare for HLN analysis seekers targeting steady growth.
ValueSense highlights its momentum through high revenue expansion and quality, appealing to portfolios balancing stability with upside in investment opportunities.
Key Catalysts
- Impressive Revenue growth of 22.2% drives expansion in consumer health
- Positive 1Y Return of 5.9% shows resilience
- Strong Quality rating 10.0 and ROIC 8.4% for quality returns
- Solid Free Cash Flow £1,396.5M enables dividends and growth
Risk Factors
- Total Debt to Equity at 52.8% could pressure in economic downturns
- Currency exposure from £-denominated metrics adds volatility
- FCF margin 10.1% trails some large-cap peers
Most investors waste time on the wrong metrics. We've spent 10,000+ hours perfecting our value investing engine to find what actually matters.
Want to see what we'll uncover next - before everyone else does?
Find Hidden Gems First!
Stock #3: Kontoor Brands, Inc. (KTB)
| Metric | Value |
|---|---|
| Market Cap | $3,398.4M |
| Quality Rating | 10.0 |
| Intrinsic Value | $72.7 |
| 1Y Return | -27.1% |
| Revenue | $2,987.6M |
| Free Cash Flow | ($13.2M) |
| Revenue Growth | 14.5% |
| FCF margin | (0.4%) |
| Gross margin | 46.2% |
| ROIC | 11.5% |
| Total Debt to Equity | 283.3% |
Investment Thesis
Kontoor Brands, Inc. (KTB) features a flawless Quality rating of 10.0 and intrinsic value of $72.7 against a Market Cap of $3,398.4M, pointing to undervaluation in apparel. It generates Revenue of $2,987.6M, though Free Cash Flow is negative at $13.2M with FCF margin 0.4%, offset by Revenue growth of 14.5%, Gross margin of 46.2%, and leading ROIC of 11.5%. A 1Y Return of -27.1% and high Total Debt to Equity of 283.3% warrant caution, but ValueSense data supports its place in KTB analysis for value-oriented stock watchlist strategies.
Despite FCF challenges, high ROIC and growth suggest turnaround potential in consumer discretionary.
Key Catalysts
- Strong Revenue growth 14.5% signals demand recovery
- Top ROIC 11.5% indicates capital efficiency
- Quality rating 10.0 underscores fundamental strength
- Gross margin 46.2% supports pricing power
Risk Factors
- Negative Free Cash Flow $13.2M and FCF margin 0.4% strain liquidity
- High Total Debt to Equity 283.3% elevates financial risk
- 1Y Return -27.1% reflects sector headwinds
Stock #4: Rezolve AI PLC (RZLV)
| Metric | Value |
|---|---|
| Market Cap | $667.6M |
| Quality Rating | 10.0 |
| Intrinsic Value | $4.3 |
| 1Y Return | -29.8% |
| Revenue | $6,451.3K |
| Free Cash Flow | ($36.6M) |
| Revenue Growth | N/A |
| FCF margin | (568.0%) |
| Gross margin | 95.4% |
| ROIC | (470.8%) |
| Total Debt to Equity | (248.8%) |
Investment Thesis
Rezolve AI PLC (RZLV), an emerging AI player, boasts a Quality rating of 10.0 and intrinsic value of $4.3 with a Market Cap of $667.6M. Metrics show Revenue of $6,451.3K, deeply negative Free Cash Flow of $36.6M and FCF margin of 568.0%, but exceptional Gross margin of 95.4%. Revenue growth is N/A, ROIC -470.8%, and Total Debt to Equity -248.8%, alongside a 1Y Return of -29.8%. This educational RZLV analysis suits high-risk, high-reward profiles in undervalued stocks to buy within AI innovation.
ValueSense positions it as a speculative momentum name with quality rating despite losses, for diversified tech exposure.
Key Catalysts
- Outstanding Gross margin 95.4% in high-tech AI segment
- Quality rating 10.0 despite early-stage challenges
- Small Market Cap $667.6M offers growth scalability
- AI focus aligns with sector momentum
Risk Factors
- Severe FCF margin 568.0% and ROIC -470.8% indicate burn rate
- Negative Total Debt to Equity -248.8% signals equity structure risks
- 1Y Return -29.8% and N/A Revenue growth heighten volatility
- Low Revenue $6,451.3K reflects pre-profit stage
Portfolio Diversification Insights
These four stocks provide balanced sector allocation across technology (WDAY, RZLV), healthcare/consumer (HLN), and consumer discretionary (KTB), reducing single-sector risk. WDAY and HLN offer stability with positive FCF and margins, countering KTB's debt load and RZLV's losses. All share Quality rating 10.0, blending large-caps ($45B+) with mid/small-caps for growth. WDAY's cash flow complements HLN's revenue surge, while KTB's ROIC and RZLV's margins add cyclical and speculative elements. This mix supports portfolio diversification in investment ideas, targeting 20-30% per sector for momentum without overexposure.
Market Timing & Entry Strategies
Consider entry during market dips when intrinsic value gaps widen, such as post-earnings for WDAY/HLN stability or AI hype cycles for RZLV. Monitor Revenue growth trends—favor HLN/KTB on upticks—and use dollar-cost averaging for volatile picks like RZLV. Track ROIC improvements and debt metrics quarterly. Position sizing: 25% in quality anchors (WDAY/HLN), 15-20% in higher-risk (KTB/RZLV). Educational framing emphasizes patience for undervaluation convergence in top stocks to buy now.
Explore More Investment Opportunities
For investors seeking undervalued companies with high fundamental quality, our analytics team provides curated stock lists:
📌 50 Undervalued Stocks (Best overall value plays for 2025)
📌 50 Undervalued Dividend Stocks (For income-focused investors)
📌 50 Undervalued Growth Stocks (High-growth potential with strong fundamentals)
🔍 Check out these stocks on the Value Sense platform for free!
More Articles You Might Like
- Nelson Peltz - Trian Fund Management Portfolio Q3'2025: Top Holdings & Recent Changes
- Principles for Dealing with the Changing World Order by Ray Dalio
- The Ascent of Money by Niall Ferguson
- Principles for Navigating Big Debt Crises by Ray Dalio
- Influence: The Psychology of Persuasion by Robert B. Cialdini Ph.D.
FAQ Section
How were these stocks selected?
These stocks were selected using ValueSense criteria emphasizing Quality rating 10.0, intrinsic value upside, strong margins, and momentum potential across sectors, as derived from provided financial metrics like ROIC and revenue growth.
What's the best stock from this list?
Haleon (HLN) edges out with positive 1Y Return 5.9%, 22.2% Revenue growth, and solid FCF, offering balanced risk-reward; however, "best" depends on individual risk tolerance and portfolio needs.
Should I buy all these stocks or diversify?
Diversification is key—allocate across these for sector balance (tech, health, consumer), avoiding full concentration; use as educational components in a broader stock watchlist.
What are the biggest risks with these picks?
Key risks include negative FCF in KTB/RZLV, high debt (KTB 283.3%), recent price declines (e.g., RZLV -29.8%), and sector volatility; monitor Total Debt to Equity and ROIC closely.
When is the best time to invest in these stocks?
Optimal timing aligns with market corrections widening intrinsic value discounts, positive earnings on growth metrics, or sector recoveries—employ gradual entry strategies for these best value stocks.